TABLE 1.
Chitosan drug delivery systems for brain targeting reported in the last 5 years.
Drug | Presentation | Application | Administration route | References |
Pentamidine | Chitosan coated niosomes | Parkinson’s disease | Intranasal | Rinaldi et al., 2019 |
Methotrexate | Chitosan hydrogel nanoparticles | Antineoplastic agent | Intravenous | Pourtalebi-Jahromi et al., 2019 |
Carbamazepine | Chitosan coated lipid nanoparticle formulation | Epilepsy | Oral | Ana et al., 2019 |
Rotigotine | Chitosan nanoparticles | Parkinson’s disease | Intranasal | Tzeyung et al., 2019 |
Doxorubicin/erlotinib | Chitosan liposomal nanoparticles | Glioblastoma | – | Lakkadwala and Singh, 2019 |
Docetaxel | TMC hydrogel | Glioblastoma | Intracranial injection | Turabee et al., 2019 |
Risperidone | Chitosan lipid nanoparticle | Schizophrenia | Intranasal | Qureshi et al., 2019 |
Pramipexole dihydrochloride | Chitosan nanoparticles | Parkinson’s Disease | Intranasal | Raj et al., 2018 |
Galantamine | Chitosan nanoparticles | Amnesia/Alzheimer | Intranasal | Sunena et al., 2019 |
Selegiline | Chitosan nanoparticles | Parkinson Disease | Intranasal | Sridhar et al., 2018 |
Temozolomide | Nano lipid chitosan hydrogel | Antineoplastic agent | Intranasal | Khan et al., 2018 |
Cyclovirobuxine d | Chitosan nanoparticles | Cerebrovascular disease | Intranasal | Wei et al., 2018 |
Diazepam | Chitosan mucoadhesive microemulsion | Status epilepticus | Intranasal | Ramreddy and Janapareddi, 2019 |
Tapentadol hydrochloride | Chitosan nanoparticles | Pain | Intranasal | Javia and Thakkar, 2017 |
Rivastigmine hydrogen tartrate | Chitosan mucoadhesive microemulsion | Cholinesterase inhibitor | Intranasal | Shah et al., 2018 |
Ribavirin | Chitosan microparticle agglomerates | Viral infection | Intranasal | Giuliani et al., 2018 |
Huperzine A | Lactoferrin-conjugated TMC surface-modified PLGA nanoparticles | Alzheimer’s disease | Intranasal | Meng et al., 2018 |
Ropinirolle-detran sulfate | Chitosan mucoadhesive neuro-nanoemulsion | Parkinson’s disease | Intranasal | Pardeshi and Belgamwar, 2018 |
Zolmitriptan | Chitosan mucoadhesive nanoemulsion | Migraine | Intranasal | Abdou et al., 2017 |
Desvenlafaxine | PLGA-chitosan nanoparticles | Depression | Intranasal | Tong et al., 2017 |
Selegiline hydrochloride | Thiolated chitosan nanoparticles | Depression | Intranasal | Singh et al., 2016 |
Quetiapine fumarate | Chitosan microemulsion | Schizophrenia | Intranasal | Shah et al., 2016 |
Rasagiline | Chitosan glutamate nanoparticles | Parkinson’s disease | Intranasal | Mittal et al., 2016 |
Ropinirole hydrochloride | Chitosan mucoadhesive nanoparticles | Parkinson’s disease | Intranasal | Jafarieh et al., 2015 |
Buspirone hydrochloride | Thiolated chitosan nanoparticles | General anxiety disorder | Intranasal | Bari et al., 2015 |
Doxepin hydrochloride | Chitosan-glycerophosphate-PEG thermoreversible biogels | Depression | Intranasal | Naik and Nair, 2014 |
Buspirone | Chitosan mucoadhesive microemulsion | General anxiety disorder | Intranasal | Bshara et al., 2014 |
Donepezil | Chitosan nanosuspension | Alzheimer disease | Intranasal | Bhavna et al., 2014 |
Levodopa | Chitosan nanoparticles | Parkinson’s Disease | Intranasal | Sharma et al., 2014 |